ICL to Acquire Majority of Lavie Bio’s Assets

Key Takeaways

• ICL to acquire the majority of Lavie Bio’s assets from Evogene, including the MicroBoost AI platform.
• The deal includes Lavie Bio’s BDD platform, microbial bank, data assets, and core team.
• Existing Lavie Bio partnerships remain with Evogene and may generate future revenue.
• The transaction strengthens ICL’s position in the biological crop solutions market.
• Expected to close in Q2 2025, pending customary approvals.

Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) has announced a definitive agreement under which ICL will acquire most of the assets and operations of its ag-biologicals subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire MicroBoost AI for AG, a computational biology platform developed by Evogene.

The acquisition follows more than two years of collaboration between the companies, including joint efforts to develop bio-stimulant solutions for row crops facing environmental stress. The transaction is expected to close in the second quarter of 2025, subject to regulatory and customary conditions.

Lavie Bio Capabilities Transferred to ICL

Lavie Bio has built a reputation as a leading player in microbiome-based agricultural solutions. The deal includes Lavie Bio’s core development team, its proprietary BDD technology platform, microbial strain bank, and associated data assets. In addition, ICL will acquire the majority of the company’s development programs and its existing commercial product portfolio.

However, Lavie Bio’s pre-existing agreements with strategic partners will remain under the ownership of Evogene and could generate future value for Lavie Bio shareholders.

“This transaction marks a significant milestone in Lavie Bio’s journey,” said Amit Noam, CEO of Lavie Bio. “By combining our capabilities with ICL’s global reach and expertise, we’re better positioned to accelerate product development and deliver meaningful solutions to growers worldwide.”

Strategic Alignment and Technological Integration

The acquisition also aligns with Evogene’s broader corporate strategy to maximize the value of its subsidiaries through commercial partnerships and targeted divestments. Evogene will retain its equity stake in Lavie Bio, while transitioning core technology and staff to ICL.

Ofer Haviv, CEO of Evogene, commented, “This agreement reflects our strategy to unlock asset value while promoting continued innovation in agriculture. We believe Lavie Bio’s integration with ICL will advance the ag-biologicals space and support the development of next-generation sustainable farming solutions.”